As much as we were excited to see Japan’s first big femtech show, we were as struck by what we didn’t see, says Alecia Thomson.
We attended the first Femtech Tokyo expo the other day, at the Tokyo Big Sight convention centre. We’ve seen smaller femtech events in Japan in the last few years, but this was the first of this scale, held at a venue which usually hosts major shows about quantum computing, automotive tech, smart factories and the like.
In this sense, it was a ground-breaking moment to see femtech finally arriving in Japan. But what we found at the event surprised us, and points to significant opportunities for western femtech firms interested in moving into the market.
What we saw – and didn’t …
We walked through the halls and attended conference sessions, including an interesting talk by Seiko Noda, former Minister for Women’s Empowerment and Gender Equality.
But, as much as we were excited to be at Japan’s first big femtech show, we were as struck by what we didn’t see at the event as what we did.
Most items on show were as general as beauty products and supplements, with no hi-tech or digital aspects at all.
Conspicuous by their absence were technologies that address the real problems women face – such as menstrual health, infertility and menopause, as well as breast, ovarian and cervical cancers.
From the video we took, you can see booth after booth of undergarments – from sanitary shorts to night bras and corrective underwear – supplements, herbal teas, Kegel trainers and CBD products.
I would hope there’s much more to femtech than protein powder in pink packaging!
Conversely, Seiko Noda talked about the serious challenges Japan needs to overcome – including its declining birth rate, an ageing population and the taboo around some women’s health issues.
She was proud to tell the crowd that last year she started the Parliamentary Assembly for the Promotion of Femtech. Through this initiative, she hopes to harness the power of technology to lighten the load for women experiencing complications with menstruation, fertility and menopause.
In fact, she highlighted that Japan is facing many unprecedented challenges where femtech can potentially help. And these are being driven to some extent by the country’s ‘womenomics’ policy to encourage more women into its shrinking work force – a significant shift, as Japan has traditionally enjoyed less female economic participation than other developed countries.
An older workforce tapping into womenomics means Japan needs to think about female employees who may be struggling with women’s health issues, as well as who is now caring for children and elderly parents back at home.
Noda’s parliamentary group is working to address many of these issues, but she called on Japanese corporations to get involved as well. And, to do that, many would benefit greatly from input from western tech firms.
Not all is doom and gloom for women in Japan, though. Formerly-taboo topics such as infertility treatment and menopause are becoming easier to talk about, according to Noda.
She also spoke about two government programmes recently rolled out: the Ministry of Economics, Trade & Industry (METI) is supporting 20 Japanese femtech startups, while the Ministry of Health, Labour & Welfare (MHLW) has been providing increased reimbursement for infertility treatments since April this year.
And, the expo aside, it’s been heartening for me to see first-hand that there’s considerable interest amongst Japanese corporations in expanding their business in the femtech space.
We’ve recently had several meeting requests from large Japanese companies wanting to learn more about femtech and to explore how western tech firms can help them.
One of our clients that has gained particular traction with Japanese corporations has been Elvie, a British femtech start-up, founded by President Tania Boler, which recently closed a Series C funding round of £70m. We’ve had the privilege of supporting the company in Japan with market research and by initiating conversations with potential partners.
Elvie has gained interest from large retailers, drugstore chains, e-commerce companies and various media outlets. And it was good to see its first product on the Japanese market – its connected pelvic floor trainer – on show at Femtech Tokyo via its Japanese partner Ajuma.
I’ve also recently supported an American/Hong Kong company developing a wearable breast cancer detection device. With breast cancer the most prevalent type amongst Japanese women, this has attracted keen interest from Japanese companies wanting to move into this space, as well as the wider medical community.
Such attention from Japanese companies is key, because western femtech firms really need in-country partners to help them address the unique characteristics of the Japanese market and to access its complex, multi-layered sales channels.
We saw wide recognition of this at Femtech Tokyo, with all but one of the western companies there exhibiting from the booths of their Japanese partners rather than going it alone.
The good news for any western firm eyeing up the market is that, given Japan’s demographic challenges and the appetite for femtech innovation amongst its corporations, the timing could not be better.
The dates for next year’s Femtech Tokyo have now been announced: 5 – 7 October 2023. We’ll be there again. And we look forward to seeing more innovative products next year – hopefully thanks to a good number of cutting-edge western tech firms.
Alecia Thomson is the Tokyo-based femtech specialist at Intralink, an international business development consultancy that helps western tech firms expand in Asia. To find out more email [email protected]
How the UK’s ‘pharmacy first’ policy will change women’s healthcare
By Katherine Bridges, head of brand and clinical lead at the pharmacy app Charac
On the January 31, the UK government will roll out its long-awaited “pharmacy first” policy, a measure designed to cut the size of the NHS backlog – which currently stands at around 7.6 million patients.
With “pharmacy first”, patients suffering from various lesser ailments – such as sore throats and shingles – will be directed to their local pharmacy as their first port of call.
Pharmacies will also be able to supply certain prescription medicines. It is hoped that this will ease pressure on Britain’s seriously overstretched hospitals and GPs.
The policy is set to transform healthcare provision in the UK, which is important for women’s health across the country. If the policy can be carried through successfully, women’s access to NHS will improve in a number of ways. The success of “pharmacy first” will, however, rely on a big technological upgrade to Britain’s 11,500 high-street pharmacies.
Improving women’s access
This shift of several key medical functions to Britain’s pharmacies will give women easier access to important medicines and treatments. For instance, under “pharmacy first” patients will be able to pick up prescription medicine for urinary tract infections (UTIs) from pharmacies; previously this required a GP appointment beforehand.
This change will be especially valuable for women, given that this ailment disproportionately affects women, with roughly 50 per cent experiencing one over the course of their lives.
Crucially, under the new policy, women will also be able to purchase contraceptive pills at their pharmacies without seeing a GP. It is vitally important, but easily prescribed and administered medications such as this that will see “pharmacy first” freeing up countless of hours of GP and hospital time.
Further, the reduction of pressure on GPs and hospitals will improve women’s access to critical medical procedures and treatments. For instance, the policy will put a dent in the NHS’s mastectomies backlog, which is currently putting thousands of women in the UK at a greater risk of breast cancer.
Femtech critical to making a success of “pharmacy first”
Of course, “pharmacy first” represents a very large administrative and operational task for Britain’s high-street pharmacies.
It is uncertain whether these pharmacies, in their current state, will be able to meet the challenge. Community pharmacies are often small and family run. As such, they find it difficult to afford key labour-saving technologies that cut costs and free up time.
These pharmacies’ internal systems are often ramshackle and antiquated. Many still run on paper, making everything from prescriptions to payroll arduous and time-consuming.
It is clear that these pharmacies will need to undergo a big technological upgrade as the policy is rolled out this year. Femtech will play a key role in this effort.
Femtech technologies could help pharmacists manage the transition to a greater scope of provision. For instance, femtech companies, such as Vivoo’s at-home women’s UTI test, could help pharmacists manage the task of treating this common women’s ailment.
Another would be the online self-assessment system Tuune, which matches women to the contraceptive treatment appropriate to their particular hormonal profile.
Innovations like these will be an essential part of women’s healthcare in the age of “pharmacy first”, driving efficiencies in high-street pharmacies and expanding women’s access to treatment.
The future of health tech will empower women
Other health technologies will help amplify the impact of femtech. Apps, such as Charac, offer a dashboard for both pharmacists and their customers, allowing customers to book pharmacy appointments and get their prescriptions delivered to their door.
These kinds of accessible, integrated health tech systems that will prove so valuable in the age of “pharmacy first” will also help improve patient outcomes for women. One of the primary hindrances to better healthcare for women is a lack of information and access.
Research by the Department of Health and Social Care revealed that around 85 per cent of British women did not feel comfortable talking to their GPs about their physical health, and a similar percentage can remember an occasion where they did not feel listened to by medical professionals.
Similarly, knowledge of women’s health issues is often low: less than one in five UK women felt that they had enough information on menstrual health, and less than one in 10 felt they knew enough about gynaecological conditions.
What’s clear is that a lack of information and access is leading to worse health outcomes for women than men, but health tech can make a valuable contribution – streamlining appointments and prescriptions, raising public awareness of health conditions and the treatment services that women can access and making patient outcomes and healthcare more equal.
As “pharmacy first” becomes policy, we have a chance to use the latest developments in femtech and health tech to both make a dent in the NHS backlog, and to put women’s healthcare on a surer foundation.
Katherine Bridges is head of brand and clinical lead at the pharmacy app Charac.
Transforming women’s health: a bold roadmap to a more equitable future
By Kavelle Christie, director of the gender equity and health justice program at Community Catalyst
Equity lies at the heart of progress, demanding a healthcare system that not only provides affordability and accessibility but also centres the distinctive needs of women.
The deliberate inequities affecting Black, Indigenous, and Latinx women, transgender women, those in rural communities, women with disabilities and those with low incomes underscore the urgent need for transformative change.
From alarming maternal mortality rates among Black and Indigenous women to abortion bans, limited healthcare access in rural areas, discriminatory practices against women with disabilities and stigmatisation faced by Black, immigrant, and transgender women, these inequities demand a comprehensive reimagining of our healthcare system.
A robust, truly transformative healthcare system is the cornerstone of a thriving society and it is time for the nation to prioritise women’s health.
Additionally, improving Black maternal health outcomes and the preservation and enhancement of reproductive rights, which encompasses unfettered access to abortion care, comprehensive family planning services and contraceptives, form other vital pillars.
Improving Black maternal health outcomes
Maternal health remains a significant concern, particularly among Black women. Passing the federal Black Maternal Health Momnibus, introduced by Rep. Underwood and Sen. Booker, can help address inequities and promote access to quality maternal care.
In addition to passing the Momnibus, it’s time for the US to invest in an ethical supply chain to ensure the improvement of necessary pre- and postpartum drug delivery. By guaranteeing the consistent availability of essential medications, we can enhance the overall quality of care.
Power and control over women’s bodies
Every woman should have the autonomy to make informed decisions about her body and reproductive health.
Policies that fail to centre marginalised communities perpetuate existing power imbalances and exacerbate health disparities. Not only is it time to pass the federal Women’s Health Protection Act to re-establish a national right to abortion to create a just healthcare system for women, but it is likewise vital to implement policies that monitor and account for the funding and actions of crisis pregnancy centres and anti-abortion maternity homes.
These often-unregulated places disseminate misleading information about abortion care, manipulate women and can come with deeply conservative ideologies, such as mandatory church service attendance in exchange for shelter and additional restrictions on reproductive choice.
Building a better healthcare system means we closely monitor and regulate crisis pregnancy centres and maternity homes, ensuring they provide comprehensive, unbiased, and evidence-based information and care to women without imposing ideological beliefs.
It is also essential to note that anti-abortionists are swiftly rolling out policies that would even prevent women from travelling on highways to access abortion services.
These predatory webs of restrictions to deprive us of our freedom are not merely about abortion rights; this is about who has power over you, who has the authority to make decisions for you and who is going to control how your future is going to be.
Therefore, to build a better healthcare system for women, we must fiercely defend abortion rights and dismantle any barriers that may obstruct women’s ability to make choices about their bodies and reproductive health.
We must give women back the power to control their own bodies, especially for those most impacted who have the least resources, who can’t afford to lose a job, who don’t have access to childcare, who have no access to healthcare and who face many more systemic barriers.
Transparency in healthcare decision-making processes is also vital. This extends to hospital ethics committees, which often make critical decisions about abortion access, but whose membership is often shrouded in secrecy.
For a more just healthcare system, we must eradicate this wall of secrecy and ensure transparency in these committees’ composition and decision-making process.
Women deserve to know that their healthcare decisions are made with impartiality and respect for their rights.
Protecting gender-affirming care
Gender-affirming care for transwomen is a critical component of comprehensive healthcare.
This specialised care involves a range of medical, psychological, and social interventions to align an individual’s physical characteristics with their gender identity. Key elements may include hormone therapy, gender confirmation surgery, mental health support, and ongoing medical monitoring.
Gender-affirming care is not only a matter of medical necessity for transwomen but is also closely tied to mental health, overall wellbeing, and a sense of self.
Creating a healthcare environment that offers inclusive, affordable, and accessible services for transwomen is essential to a holistic approach that acknowledges and validates their gender identity, ultimately contributing to better health outcomes and improved quality of life.
Kavelle Christie is the director of the gender equity and health justice program at Community Catalyst, a national health advocacy organisation that works alongside organisational partners across 45 states and territories to build people power and create a health system rooted in race equity and health justice.
The impact of menopause and ageing on urinary incontinence in women
By Lydia Zeller, CEO at Pelvital USA
The natural processes of menopause and ageing are not the biggest challenge women face when it comes to incontinence. The biggest challenges are the historic silence and assumption that our only options are pads or surgery.
One of the most rewarding aspects of my role as CEO of Pelvital is amplifying the conversation around women’s health, especially on historically stigmatised topics like urinary incontinence (UI) and menopause.
If you suffer from bladder leaks, you’re not alone. Research from 2022 shows more than 60 per cent of US women suffer some form of bladder leaks. It is unacceptable that an issue impacting over half of women has historically been kept quiet and stigmatised.
Women are led to believe that bladder leaks are a natural part of being a mum or growing older. That is not true. Although bladder leaks are common, they are not normal, and women should not accept them as such.
Fortunately, there are effective options for treating leaks and education is the first step in self-advocacy – one of the reasons why I love talking about this topic.
First, let’s talk about the different types of UI. Stress urinary incontinence presents as accidental leakage associated with activities like sneezing, laughing, coughing, or jumping.
Urge incontinence (including overactive bladder) involves the sudden urge to urinate followed by involuntary loss of urine. Mixed incontinence is the combination of stress and urge incontinence. Stress urinary incontinence (SUI) is the most common form and is often caused by weakened pelvic floor muscles.
While one in three mothers report SUI within three months of childbirth, UI prevalence indisputably increases with age: 62 per cent of women in their 40s have UI compared to 68 per cent of women in their 50’s, 72 per cent in their 60s and 83 per cent in their 70s.
But does menopause cause incontinence? Yes and no.
Menopause is defined as the natural event of a woman’s final menstrual cycle. It is associated with reduced functioning of the ovaries due to ageing, resulting in lower levels of oestrogen, progesterone, and testosterone.
While these steep hormonal drops don’t directly cause incontinence, they cause thinning of the tissues in the pelvic floor muscles during perimenopause (the time around menopause when your ovaries gradually stop working).
Combine this thinning with common unresolved pelvic floor weakness or injury (e.g. caused by pregnancy, childbirth, pelvic surgery, falls) and/or with common changes associated with ageing (e.g. lowered fluid intake, lowered activity, constipation) – and urinary incontinence can result.
Stress urinary incontinence is most often caused by weak pelvic floor muscles – and menopause-related changes exacerbate that weakness.
Pelvital on-staff pelvic health doctors of physical therapy Shravya Kovela and Leah Fulker describe how this works in a blog on the menopause / incontinence connection: Weak pelvic floor muscles are unable to contract properly to close the urethral sphincter where urine escapes the body.
When paired with hormonal changes of menopause and the resulting changes in tissue flexibility or elasticity of the vulva, vagina, and urethral sphincter, urinary incontinence will appear or worsen.
Furthermore, discomfort in the vulva and vagina associated with menopause-related vaginal dryness or pain may lead pelvic floor muscles to compensate, worsening urinary incontinence.
Interestingly, menopause and ageing do not equally impact incontinence. Menopause transition has been found to correlate with stress urinary incontinence, whereas increasing age and risk factors such as anxiety, BMI, and new onset diabetes correlate with both stress and urge incontinence. And new onset of SUI is highest in perimenopause as opposed to postmenopause.
But the natural processes of menopause and ageing are not the biggest challenge women face when it comes to incontinence. The biggest challenges are the historic silence and assumption that our only options are pads or surgery.
Tragically, according to the Study of Women’s Health Across the Nation (SWAN) – a historic study to define menopause transition and “characterise its biological and psychosocial antecedents and sequelae in an ethnically and racially diverse sample of midlife women” – fewer than 40 per cent of incontinent women even seek treatment from their healthcare provider.
Women are uncomfortable bringing this topic up with their providers and when they do, too often are dismissed without options.
Menopause gaslighting is occurring to women because historically there has been a significant lack of clinically proven conservative options for women who do not wish to have surgery.
Pelvic floor physical therapy has been the shining light here, but a mere one per cent of physical therapists specialise in the pelvic floor, resulting in significant access gaps.
The continued uptick in virtual pelvic health physical therapy options is a big positive, increasing access and enabling women to fit treatment into their lives. Similarly, evidence-based in-home treatment options allow women flexibility and clinicians the ability to extend their clinic walls and deliver conservative care at scale, with outcomes very similar to surgery.
This conversation is incomplete without mention of economics and gender equity. Not only has research into women’s health been historically massively underfunded, but women bear disproportionate out-of-pocket costs.
Specific to UI, 70 per cent of costs are borne by the woman. And that is also completely unacceptable. I am proud to be part of the growing cohort of femtech companies creating change and step by step moving towards broad access and insurance coverage. Women deserve no less.
Lydia Zeller is CEO at Pelvital USA, Inc., a Minnesota based femtech company providing products to restore pelvic floor health. Flyte by Pevital is an FDA-cleared novel in-home treatment for female urinary incontinence.
- Menopause start-up raises US$3.3m to expand digital health platform
- Women’s cancer innovation to take centre stage at Femtech World Awards
- Tech4Eva launches its fourth edition and call for application
- Investors launch female-focused angel network in the north of England
- US maternity clinic raises a US$28m to expand nationally
Receive updates from Femtech World
News2 weeks ago
US pregnancy care platform bags US$2.4m to ‘redefine’ maternal health
News2 days ago
Medtech start-up raises €15 to “shape” the future of medical imaging
Entrepreneur4 weeks ago
Menstrual health: how ‘donating your period’ could advance women’s health
News2 weeks ago
Everything you need to know about preeclampsia
Femtech World Awards3 weeks ago
Ground-breaking research to be celebrated at Femtech World Awards
News7 days ago
Start-up secures Series A funding round for wearable urinary incontinence device
Fertility2 weeks ago
Partnership to pilot ‘cutting-edge’ embryo selection tool
News2 days ago
Irish clinic launches menopause app to help researchers develop new treatments